WCG Wealth Advisors LLC Purchases New Stake in GSK plc (NYSE:GSK)

WCG Wealth Advisors LLC acquired a new stake in shares of GSK plc (NYSE:GSK) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 11,930 shares of the pharmaceutical company’s stock, valued at approximately $459,000.

Other large investors have also bought and sold shares of the company. Register Financial Advisors LLC bought a new position in GSK during the 1st quarter valued at $31,000. Ashton Thomas Private Wealth LLC bought a new position in GSK during the 2nd quarter valued at $37,000. Richardson Financial Services Inc. bought a new position in GSK during the 4th quarter valued at $40,000. PrairieView Partners LLC bought a new position in GSK during the 2nd quarter valued at $47,000. Finally, Triad Wealth Partners LLC bought a new position in GSK during the 2nd quarter valued at $49,000. 15.74% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Argus upgraded GSK to a “strong-buy” rating in a research note on Wednesday, August 7th. The Goldman Sachs Group started coverage on GSK in a research note on Thursday, May 30th. They set a “neutral” rating and a $47.00 target price on the stock. Citigroup upgraded GSK to a “strong-buy” rating in a research note on Monday, June 24th. Barclays upgraded GSK to a “hold” rating in a research note on Tuesday, August 27th. Finally, Jefferies Financial Group lifted their target price on GSK from $52.50 to $53.00 and gave the stock a “buy” rating in a research note on Tuesday, July 2nd. Four analysts have rated the stock with a hold rating, two have assigned a buy rating and four have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, GSK has a consensus rating of “Buy” and an average target price of $50.00.

GSK Trading Down 1.8 %

Shares of GSK stock opened at $41.65 on Friday. GSK plc has a 52-week low of $33.67 and a 52-week high of $45.92. The stock’s 50-day simple moving average is $41.36 and its 200 day simple moving average is $41.71. The stock has a market capitalization of $86.32 billion, a P/E ratio of 15.09, a P/E/G ratio of 1.41 and a beta of 0.66. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.54 and a current ratio of 0.82.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.00 by $0.09. GSK had a return on equity of 51.48% and a net margin of 12.87%. The business had revenue of $9.95 billion for the quarter, compared to analysts’ expectations of $9.49 billion. As a group, research analysts anticipate that GSK plc will post 4.15 EPS for the current year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 10th. Investors of record on Friday, August 16th will be paid a $0.3843 dividend. This is a boost from GSK’s previous quarterly dividend of $0.38. This represents a $1.54 dividend on an annualized basis and a yield of 3.69%. The ex-dividend date of this dividend is Friday, August 16th. GSK’s payout ratio is currently 54.71%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.